Étude des facteurs pronostiques pour le carcinome rénal métastatique traité par une deuxième ligne de thérapies ciblées

Gupta, 2008, Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review, Cancer Treat Rev, 34, 193, 10.1016/j.ctrv.2007.12.001 Méjean, 2008, Prise en charge du cancer rénal métastatique, Prog Urol, 18, S298, 10.1016/S1166-7087(08)74558-5 Ko, 2015, The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study, Lancet Oncol, 16, 293, 10.1016/S1470-2045(14)71222-7 Escudier, 2010, How to select targeted therapy in renal cell cancer, Ann Oncol, 21, vii59, 10.1093/annonc/mdq371 Sun, 2011, Prognostic factors and predictive models in renal cell carcinoma: a contemporary review, Eur Urol, 60, 644, 10.1016/j.eururo.2011.06.041 Patard, 2013, Recommendations onco-urology 2013: kidney cancer, Prog Urol, 23, S177, 10.1016/S1166-7087(13)70055-1 Ljungberg, 2010, EAU guidelines on renal cell carcinoma: the 2010 update, Eur Urol, 58, 398, 10.1016/j.eururo.2010.06.032 Motzer, 2002, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J Clin Oncol, 20, 289, 10.1200/JCO.20.1.289 Di Fiore, 2011, Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib, Br J Cancer, 105, 1811, 10.1038/bjc.2011.507 Bono, 2011, Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma, Acta Oncol, 50, 569, 10.3109/0284186X.2010.543696 Poprach, 2012, Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study, Ann Oncol, 23, 3137, 10.1093/annonc/mds145 Heng, 2009, Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study, J Clin Oncol, 27, 5794, 10.1200/JCO.2008.21.4809 Levy, 2013, Second line treatment of metastatic renal cell carcinoma: the Institut Gustave-Roussy experience with targeted therapies in 251consecutive patients, Eur J Cancer, 49, 1898, 10.1016/j.ejca.2013.02.003 Wong, 2015, Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States, Expert Opin Pharmacother, 16, 805, 10.1517/14656566.2015.1020298 Nouhaud, 2014, Valeur pronostique de la toxicité induite par les thérapies ciblées dans le carcinome rénal métastatique, Prog Urol, 24, 563, 10.1016/j.purol.2013.12.001 Josephs, 2011, Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis, BJU Int, 108, 1279, 10.1111/j.1464-410X.2010.09990.x Macfarlane, 2012, The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy, Cancer, 118, 365, 10.1002/cncr.26201 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Rini, 2011, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase3 trial, Lancet, 378, 1931, 10.1016/S0140-6736(11)61613-9 Nouhaud, 2015, Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma, Anticancer Drugs, 10.1097/CAD.0000000000000253